Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer

To identify an MTD of olaparib, a PARP inhibitor, in combination with loco-regional radiotherapy with/without cisplatin for the treatment of non-small cell lung cancer (NSCLC). Olaparib dose was escalated in two groups: radiotherapy (66 Gy/24 fractions in 2.75 Gy/fraction) with and without daily cis...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2021-03, Vol.27 (5), p.1256-1266
Main Authors: de Haan, Rosemarie, van den Heuvel, Michel M, van Diessen, Judi, Peulen, Heike M U, van Werkhoven, Erik, de Langen, Adrianus J, Lalezari, Ferry, Pluim, Dick, Verwijs-Janssen, Manon, Vens, Conchita, Schellens, Jan H M, Steeghs, Neeltje, Verheij, Marcel, van Triest, Baukelien
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Chemoradiotherapy - mortality
Cisplatin - administration & dosage
Female
Follow-Up Studies
Humans
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Maximum Tolerated Dose
Middle Aged
Phthalazines - administration & dosage
Piperazines - administration & dosage
Prognosis
Radiotherapy Dosage
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To identify an MTD of olaparib, a PARP inhibitor, in combination with loco-regional radiotherapy with/without cisplatin for the treatment of non-small cell lung cancer (NSCLC). Olaparib dose was escalated in two groups: radiotherapy (66 Gy/24 fractions in 2.75 Gy/fraction) with and without daily cisplatin (6 mg/m ), using time-to-event continual reassessment method with a 1-year dose-limiting toxicity (DLT) period. The highest dose level with a DLT probability
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-20-2551